Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, shared data from its AL003 and
AL101 programs in poster presentations at the 14th Clinical Trials
on Alzheimer's Disease (CTAD) conference being held November 9-12,
2021, virtually and in Boston.
“Since our formation, Alector has established a deep pipeline of
therapeutic immuno-neurology candidates, each of which aims to
harness the body’s innate immune system to slow the progression of
neurodegenerative diseases. The presentations at this year’s
CTAD conference highlight the diverse genetically validated targets
we have in our portfolio and the progress being achieved across our
pipeline,” said Sam Jackson, interim Chief Medical Officer of
Alector. “We’re presenting data from two Phase 1
clinical-stage candidates, AL003 and AL101, each with a distinct
profile. AL003 has a mechanism analogous to the checkpoint
inhibitors used in oncology and is intended to restore appropriate
innate immune system function and allow the brain’s immune cells to
do their job in maintaining a healthy equilibrium. AL101
builds on the success we’ve observed with our lead candidate,
AL001, with the intent of offering optimized dosing while
increasing progranulin levels. We will continue to advance
both candidates into further clinical studies in the coming
months.”
Alector management will host a conference call to review and
discuss data presented this week for four of its pipeline
candidates at the CTAD conference and at the Society for
Immunotherapy of Cancer (SITC) on November 12, 2021, at 4:00 p.m.
ET.
AL003: Phase 1 Data in Healthy Volunteers and
Participants with Alzheimer’s DiseaseAL003 is a humanized
monoclonal antibody that targets Siglec3 (sialic acid binding
Ig-like lectin 3), or CD33, a transmembrane receptor expressed by
microglia cells in the brain. The Phase 1 INTERCEPT
(NCT03822208) study is a randomized, placebo-controlled trial
evaluating the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and immunogenicity of single and multiple
doses of AL003 in healthy volunteers and patients with
mild-to-moderate Alzheimer’s disease. In this first-in-human
study, AL003 showed a favorable safety and pharmacokinetic profile
for once-monthly intravenous dosing. AL003 demonstrated
target engagement of CD33 in both blood and central nervous system
(CNS) compartments at well tolerated doses.
AL003 is being developed in collaboration with Abbvie. A
randomized, controlled Phase 2 trial evaluating AL003 for the
treatment of early Alzheimer’s disease is being planned for the
second half of 2022.
AL101: Interim Results from a First-in-Human
Study AL101 is a human monoclonal antibody that blocks the
sortilin receptor to increase progranulin, a regulator of immune
activity in the brain with genetic links to multiple
neurodegenerative disorders. The Phase 1 study (NCT04111666)
of AL101 enrolled a total of 55 healthy volunteers in six cohorts
to test the safety, tolerability, PK, PD and bioavailability of
single doses of intravenously or subcutaneously administered
AL101.
Study participants were randomized on a 3:8 basis to receive
placebo or a single dose of AL101. The majority of the
participants received a single IV infusion of AL101 in doses
ranging from 6mg/kg to 60mg/kg. Another cohort received 600
mg of AL101 by subcutaneous injection. AL101 was found to be
generally safe and well tolerated. The majority of on-study
adverse events (AEs) were considered mild to moderate in severity,
with the most frequent AEs being headache, anemia and procedural
pain. Three serious adverse events were reported, but two
were considered unrelated to treatment; the third was indicative of
an infusion reaction. AL101 exposure increased in a
dose-proportional manner after single ascending intravenous doses.
The study also established that AL101 was effectively
distributed into the central nervous system, as evidenced by
cerebrospinal fluid concentrations of AL101. Further, study
results show proof of mechanism for AL101; increases in progranulin
levels were observed in the periphery and the brain persisting for
one month. Alector is continuing to enroll additional cohorts to
test further dosages of AL101 administered intravenously and
subcutaneously.
AL101 is being developed under Alector’s collaboration with
GlaxoSmithKline (GSK), and the Phase 1 study is ongoing.
AL101 is the second of Alector’s progranulin-elevating therapeutic
agents and is designed for less frequent dosing.
Data for AL003 and AL101, as well as a trial design poster for
the Phase 3 INFRONT-3 clinical trial of AL001, are being presented
at CTAD in poster presentations. The posters are available on
the CTAD conference website and will be made available on the
Investors section of the Alector website
- A Phase 1 Study of AL003 in Healthy Volunteers and Participants
with Alzheimer’s Disease (P45)
- A First-in-human Study of the Anti-Sortilin Antibody AL101
(P46)
- Design of INFRONT-3: A Phase 3 Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy and Safety of
AL001 IN FTD-GRN (P71)
About AL003AL003 targets CD33, or sialic acid
binding Ig-like lectin 3 (Siglec-3), a known a genetic risk factor
for Alzheimer’s disease. Siglec-3 is an inhibitory receptor
expressed primarily on cells of myeloid lineage including
microglia, which constitute the brain’s immune system.
Mutations or overexpression of CD33 are understood to suppress
healthy microglial activity and enable the build-up of toxic
proteins, such as beta amyloid. AL003 is a monoclonal
antibody that works by decreasing the expression of Siglec-3 to
increase the activity of microglia. By inhibiting
Siglec-3/CD33 expression, AL003 is intended to reverse inhibition
of immune cell activity and restore homeostasis. AL003 is
being developed by Alector in collaboration with AbbVie.
About AL101AL101 is a human monoclonal antibody
designed to increase progranulin, a regulator of immune activity in
the brain with genetic links to multiple neurodegenerative
disorders. Mutations that moderately reduce the expression
levels of progranulin have been shown to increase the risk of
developing Alzheimer’s disease and Parkinson’s disease, and
increased progranulin levels have been demonstrated to be
protective for these diseases in animal models.
AL101 received orphan drug designation from the U.S. Food and
Drug Administration for the treatment of frontotemporal dementia in
July 2019. In July 2021, Alector and GSK announced a global
collaboration to co-develop and co-commercialize two
progranulin-elevating candidates, AL001 and AL101, for a range of
neurodegenerative diseases, including frontotemporal dementia,
amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s
disease.
About Alzheimer’s DiseaseAlzheimer’s disease is
a degenerative brain disease and the most common form of dementia.
It is an irreversible, progressive brain disorder that slowly
destroys memory and thinking skills, and eventually the ability of
patients to care for themselves. In most people with Alzheimer’s
disease, symptoms first appear in their mid-60s. The Alzheimer’s
Association estimates that as of 2020, there are 5.8 million
Americans aged 65 and older living with Alzheimer’s disease, and
projects that number will rise to nearly 14 million by 2050.
About AlectorAlector is a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a
root cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a
broad portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable the rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s
immuno-neurology product candidates are supported by biomarkers and
target genetically defined patient populations in frontotemporal
dementia and Alzheimer’s disease. This scientific approach is
also the basis for the company’s immuno-oncology programs.
Alector is headquartered in South San Francisco, California. For
additional information, please visit www.alector.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to numerous important factors, risks and uncertainties
that may cause actual events or results to differ materially from
current expectations and beliefs, including but not limited to
risks and uncertainties related to market conditions, Alector and
its business as set forth in our Quarterly Report on Form 10-Q, as
filed on November 4, 2021 with the Securities and Exchange
Commission (“SEC”), as well as the other documents Alector files
from time to time with the SEC. These documents contain and
identify important factors that could cause the actual results for
Alector to differ materially from those contained in Alector’s
forward-looking statements. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Alector specifically disclaims any obligation to update any
forward-looking statement, except as required by law.
Alector ContactsMichelle Corral VP,
Communications and Investor
Relations650-808-7016michelle.corral@alector.com
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Laura Perry/Eric Kasper Argot Partners
212.600.1902 alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024